Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by Habibollah Mahmoodzadeh
Total Records ( 2 ) for Habibollah Mahmoodzadeh
  Ghanbar Mahmoodi Chalbatani , Hassan Dana , Elahe Gharagozlou , Habibollah Mahmoodzadeh , Elham Zeinalinia , Omaid Rezaeian , Parisa Pilvar , Milad Ardaneh , Saeed Meghdadi , Fereidoon Memari and Nargesyousefi Rad
  MicroRNAs are small noncoding RNAs with lengths of 21-22 nucleotides that participate in post-transcriptional control of gene expression. According to recent studies, 2588 microRNAs have been detected and the list is growing. Furthermore, microRNA (miRNA) plays a major role in regulating biological processes and miRNA in relation to many diseases including cancer. The deregulation connection between miRNA and cancer was discovered in 2002. Today, even more information about the main role that miRNA plays in cancer development has been uncovered, however, there is still a long way to go to understand the functions of all the microRNAs in eukaryotes. In this review, briefly explained miRNA biogenesis and discuss the roles that miRNAs play in cancer development. Finally, discussed how miRNAs can be used as biomarkers and as a new therapeutic approach in cancer.
  Fatemeh Nouri Rouzbahani , Mohammad Shirkhoda , Feridon Memari , Hassan Dana , Ghanbar Mahmoodi Chalbatani , Habibollah Mahmoodzadeh , Nasim Samarghandi , Elahe Gharagozlou , Mohammad Hosein Mohammadi Hadloo , Ali Reza Maleki , Ehsan Sadeghian , ElhamZainali Nia , Nedazainali Nia , Farimah Hadjilooei , Omid Rezaeian , Saeed Meghdadi , SeyedRohollah Miri , Fatameh Jafari , Elham Rayzan and Vahid Marmari
  Cancer is a major burden of disease worldwide with considerable impact on society. The tide of immunotherapy has finally changed after decades of disappointing results and has become a clinically validated treatment for many cancers. Immunotherapy takes many forms in cancer treatment, including the adoptive transfer of ex vivo activated T cells, oncolytic viruses, natural killer cells, cancer vaccines and administration of antibodies or recombinant proteins that either costimulate cells or block the so-called immune checkpoint pathways. Recently, cancer immunotherapy has received a high degree of attention, which mainly contains the treatments for programmed death ligand 1 (PD-L1), programmed death 1 (PD-1), chimeric antigen receptors (CARs) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). Here, this paper reviewed the current understandings of the main strategies in cancer immunotherapy (adoptive cellular immunotherapy, immune checkpoint blockade, oncolytic viruses and cancer vaccines) and discuss the progress in the synergistic design of immune-targeting combination therapies.
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility